Safety and immunogenicity of meningococcal (Groups A and C) polysaccharide vaccine in children 2 to 6 y of age in China: a randomized, active-controlled, non-inferiority study

References

• Pace D, Pollard AJ. Meningococcal disease: clinical presentation and sequelae. Vaccine. 2012;30(Suppl 2):B3–9. doi:10.1016/j.vaccine.2011.12.062.
   PubMed Web of Science ®Google Scholar
• World Health Organization (WHO). Meningococcal meningitis - Fact sheet. Geneva (Switzerland): World Health Organization (WHO); 2018.
   Google Scholar
• Harrison LH, Pelton SI, Wilder-Smith A, Holst J, Safadi MA, Vazquez JA, Taha M-K, LaForce FM, Von Gottberg A, Borrow R, et al. The global meningococcal initiative: recommendations for reducing the global burden of meningococcal disease. Vaccine. 2011;29(18):3363–71. doi:10.1016/j.vaccine.2011.02.058.
   PubMedGoogle Scholar
• Xie O, Pollard AJ, Mueller JE, Norheim G. Emergence of serogroup X meningococcal disease in Africa: need for a vaccine. Vaccine. 2013;31:2852–61. doi:10.1016/j.vaccine.2013.04.036.
   PubMed Web of Science ®Google Scholar
• Rouphael NG, Stephens DS. Neisseria meningitidis: biology, microbiology, and epidemiology. Methods Mol Biol. 2012;799:1–20.
   PubMedGoogle Scholar
• Wang JF, Caugant DA, Li X, Hu X, Poolman JT, Crowe BA, Achtman M. Clonal and antigenic analysis of serogroup A Neisseria meningitidis with particular reference to epidemiological features of epidemic meningitis in the People’s Republic of China. Infect Immun. 1992;60:5267–82. doi:10.1128/IAI.60.12.5267-5282.1992.
   PubMed Web of Science ®Google Scholar
• Li J, Li Y, Yin Z, Yang J, Shao Z, Ning X. [Epidemiological analysis of the meningococcal disease in China during 1997–2006]. Chin J Vacc Immunization. 2007;13:453–56.
   Google Scholar
• Chen M, Guo Q, Wang Y, Zou Y, Wang G, Zhang X, Xu X, Zhao M, Hu F, Qu D, et al. Shifts in the antibiotic susceptibility, serogroups, and clonal complexes of Neisseria meningitidis in Shanghai, China: a time trend analysis of the pre-quinolone and quinolone eras. PLoS Med. 2015;12(6):e1001838. doi:10.1371/journal.pmed.1001838.
   PubMed Web of Science ®Google Scholar
• Li J, Shao Z, Liu G, Bai X, Borrow R, Chen M, Guo Q, Han Y, Li Y, Taha M-K, et al. Meningococcal disease and control in China: findings and updates from the Global Meningococcal Initiative (GMI). J Infect. 2018;76(5):429–37. doi:10.1016/j.jinf.2018.01.007.
   PubMed Web of Science ®Google Scholar
• Li J, Li Y, Shao Z, Li L, Yin Z, Ning G, Xu L, Luo H. Prevalence of meningococcal meningitis in China from 2005 to 2010. Vaccine. 2015;33(8):1092–97. doi:10.1016/j.vaccine.2014.10.072.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Wei D, Guo X, Han M, Yuan L, Kyaw MH. Burden of Neisseria meningitidis infections in China: a systematic review and meta-analysis. J Glob Health. 2016;6:020409. doi:10.7189/jogh.06.020409.
   PubMed Web of Science ®Google Scholar
• Shao Z, Li W, Ren J, Liang X, Xu L, Diao B, Li M, Lu M, Ren H, Cui Z, et al. Identification of a new Neisseria meningitidis serogroup C clone from Anhui province, China. Lancet. 2006;367(9508):419–23. doi:10.1016/S0140-6736(06)68141-5.
   PubMed Web of Science ®Google Scholar
• Zhang X, Shao Z, Zhu Y, Xu L, Xu X, Mayer LW, Xu J, Jin Q. Genetic characteristics of serogroup A meningococci circulating in China, 1956-2005. Clin Microbiol Infect. 2008;14:555–61. doi:10.1111/j.1469-0691.2008.01977.x.
   PubMed Web of Science ®Google Scholar
• Yang L, Shao Z, Zhang X, Xu L, Peng J, Xu X, Liang X, Qi Y, Jin Q. Genotypic characterization of Neisseria meningitidis serogroup B strains circulating in China. J Infect. 2008;56(3):211–18. doi:10.1016/j.jinf.2007.12.005.
   PubMed Web of Science ®Google Scholar
• Zhang TG, Chen C, He JG, Wu J, Chen LJ, Pang XH, Yang J, Shao ZJ, Huang YC. Molecular characterizations of serogroup B Neisseria meningitidis strains circulating in Beijing. Chin Med J (Engl). 2009;122:584–87. PMID 19323912.
   PubMed Web of Science ®Google Scholar
• Xu XH, Ye Y, Hu LF, Jin YH, Jiang QQ, Li JB. Emergence of serogroup C meningococcal disease associated with a high mortality rate in Hefei, China. BMC Infect Dis. 2012;12:205. doi:10.1186/1471-2334-12-205.
   PubMed Web of Science ®Google Scholar
• Zhou H, Liu W, Xu L, Deng L, Deng Q, Zhuo J, Shao Z. Spread of Neisseria meningitidis serogroup W clone, China. Emerg Infect Dis. 2013;19:1496–99. doi:10.3201/eid1909.130160. PMID 23965378.
   PubMed Web of Science ®Google Scholar
• World Health Organization (WHO). Requirements for meningococcal polysaccharide vaccine. World Health Organ Tech Rep Ser; Geneva, Switzerland; 1976.
   Google Scholar
• Wong KH, Barrera O, Sutton A, May J, Hochstein DH, Robbins JD, Robbins JB, Parkman PD, Seligmann EB Jr. Standardization and control of meningococcal vaccines, group A and group C polysaccharides. J Biol Stand. 1977;5:197–215. doi:10.1016/S0092-1157(77)80005-X. PMID 408354.
   PubMedGoogle Scholar
• Jodar L, Cartwright K, Feavers IM. Standardisation and validation of serological assays for the evaluation of immune responses to Neisseria meningitidis serogroup A and C vaccines. Biologicals. 2000;28:193–97. doi:10.1006/biol.2000.0253.
   PubMedGoogle Scholar
• Borrow R, Andrews N, Goldblatt D, Miller E. Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: reevaluation of correlates of protection. Infect Immun. 2001;69:1568–73. doi:10.1128/IAI.69.3.1568-1573.2001.
   PubMed Web of Science ®Google Scholar
• Granoff DM, Pollard AJ. Reconsideration of the use of meningococcal polysaccharide vaccine. Pediatr Infect Dis J. 2007;26:716–22. doi:10.1097/INF.0b013e3180cc2c25.
   PubMed Web of Science ®Google Scholar
• Arakere G, Frasch CE. Specificity of antibodies to O-acetyl-positive and O-acetyl-negative group C meningococcal polysaccharides in sera from vaccinees and carriers. Infect Immun. 1991;59:4349–56. doi:10.1128/IAI.59.12.4349-4356.1991.
   PubMed Web of Science ®Google Scholar
• Apicella MA, Feldman HA. Meningococcal group C subgroup determinant detected by immunofluorescence. Proc Soc Exp Biol Med. 1976;152:289–91. doi:10.3181/00379727-152-39381.
   PubMed Web of Science ®Google Scholar
• Borrow R, Longworth E, Gray SJ, Kaczmarski EB. Prevalence of de-O-acetylated serogroup C meningococci before the introduction of meningococcal serogroup C conjugate vaccines in the United Kingdom. FEMS Immunol Med Microbiol. 2000;28:189–91. doi:10.1111/j.1574-695X.2000.tb01475.x.
   PubMed Web of Science ®Google Scholar
• Michon F, Huang CH, Farley EK, Hronowski L, Di J, Fusco PC. Structure activity studies on group C meningococcal polysaccharide-protein conjugate vaccines: effect of O-acetylation on the nature of the protective epitope. Dev Biol (Basel). 2000;103:151–60.
   PubMedGoogle Scholar
• Richmond P, Borrow R, Findlow J, Martin S, Thornton C, Cartwright K, Miller E. Evaluation of De-O-acetylated meningococcal C polysaccharide-tetanus toxoid conjugate vaccine in infancy: reactogenicity, immunogenicity, immunologic priming, and bactericidal activity against O-acetylated and De-O-acetylated serogroup C strains. Infect Immun. 2001;69:2378–82. doi:10.1128/IAI.69.4.2378-2382.2001.
   PubMed Web of Science ®Google Scholar
• Fusco PC, Farley EK, Huang CH, Moore S, Michon F. Protective meningococcal capsular polysaccharide epitopes and the role of O acetylation. Clin Vaccine Immunol. 2007;14:577–84. doi:10.1128/CVI.00009-07.
   PubMed Web of Science ®Google Scholar